Phase 2 N=116 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Adult Rhabdomyosarcoma · Adult Synovial Sarcoma · Childhood Hepatoblastoma
Primary: Disease Response — 10; 10; 19; 10 patient
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Recurrent Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: MTD/RP2D of Pevonedistat in Combination With Irinotecan and Temozolomide — 35 mg/m^2
Phase 2 N=35 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Phase 2 N=20 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Best Overall Response Rate (ORR) — 2 Participants
Phase 2 N=19 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Phase 2 N=26 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Phase 2 N=140 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Metastatic Melanoma · Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Recurrent Hodgkin Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab — 0; 0; 5; 0 Participants
Phase 2 N=139 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Small Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors
Primary: Overall Survival — 6.85; 7.6; 7.5 Months
Phase 2 N=29 Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 3; 15; 5 Participants
Phase 2 N=20 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Phase 1 N=59 Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Malignant Glioma · Recurrent Brain Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: Number of Dose Limiting Toxicities of Selinexor — 0; 4; 1; 2 Participants
Phase 2 N=23 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Phase 2 N=13 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
Carcinoma, Small Cell · Lung Cancer · Small Cell Lung Cancer
Primary: Proportion of Evaluable Participants Who Experience a Partial Response (PR) or Complete Response (CR) Reported Along With an 80% Confidence Interval. — 0.1; 0; 0.2; 0…
Phase 2 N=22 Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
Recurrent Small Cell Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Overall Response Rate (Phase II) — 0; 0; 0; 0 participants
Phase 2 N=32 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Phase 2 N=4 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Phase 1 N=33 Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Childhood Solid Neoplasm · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: Number of Patients With Cycle 1 and 2 Dose Limiting Toxicities Attributable to Nanoparticle Albumin-bound Rapamycin — 1; 2; 1; 1 Participants
Phase 2 N=48 Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Phase 2 N=57 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants
Phase 2 N=19 Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Phase 2 N=16 Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Cancer
Primary: Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin — 0; 0; 0; 0 Participants
Phase 2 N=345 Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Phase 2 N=25 Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants
Phase 2 N=52 Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Solid Tumor, Adult
Primary: Immune-related Objective Response Rate — 9 Participants
Phase 2 N=40 Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Adult Solid Neoplasm · Childhood Solid Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: The Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose of Temozolomide and Talazoparib Combination Therapy — 0; 0; 1; 2…
Phase 2 N=3 Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) — 2; 0 Participants
Phase 2 N=56 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
Phase 2 N=21 Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Phase 2 N=113 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Solid Tumor
Primary: Number of Participants With Adverse Events (AEs). — 8; 6; 12; 7 Participants
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants